---
id: 228
title: Prosthetic Joint Infection (PJI)
category: clinical_syndromes
subcategory: bone_joint
tags: [prosthetic-joint-infection, PJI, hip-arthroplasty, knee-arthroplasty, MRSA, biofilm, DAIR]
difficulty: high
---

## Question

How is prosthetic joint infection managed? Use **"Early (<3mo): DAIR + Antibiotics × 3-6mo, Chronic: 2-Stage Exchange"** framework.

## Answer

### **Definition:**

**Prosthetic Joint Infection (PJI):**
- **Infection of prosthetic joint** (hip, knee most common)
- **Biofilm formation** on prosthesis (difficult to eradicate with antibiotics alone)

### **Classification:**

**Early Postoperative (<3 Months):**
- **Surgical site infection** → prosthesis infection
- **Organisms:** *S. aureus*, Gram-negatives
- **May retain prosthesis** (DAIR) if diagnosed early

**Delayed (3-24 Months):**
- **Low-virulence organisms** (CoNS, *Cutibacterium*)
- **Indolent course**
- **Often requires 2-stage exchange**

**Late Hematogenous (>24 Months):**
- **Bacteremia** → hematogenous seeding
- **Organisms:** *S. aureus*, Streptococci
- **May retain prosthesis** (DAIR) if acute, well-fixed prosthesis

### **Clinical Presentation:**

**Early/Acute:**
- **Fever, pain, erythema, warmth** over joint
- **Purulent drainage** from surgical site
- **Acute onset** (days to weeks post-op)

**Chronic/Indolent:**
- **Persistent pain** (especially with weight-bearing)
- **Prosthesis loosening**
- **Sinus tract** (chronic draining wound)
- **No fever** (often afebrile)

### **Diagnosis:**

**Modified MSIS (Musculoskeletal Infection Society) Criteria:**

**Definite PJI (≥1 Major OR ≥4 Minor):**

**Major Criteria:**
1. **Sinus tract** communicating with prosthesis
2. **Same organism** ≥2 cultures (tissue/synovial fluid)

**Minor Criteria (Need ≥4):**
1. Elevated serum CRP (>10 mg/L) OR ESR (>30 mm/h)
2. Elevated synovial WBC (>3,000/μL) OR PMN% (>70%)
3. Elevated synovial α-defensin
4. Positive histology (≥5 PMNs per HPF)
5. Single positive culture

**Arthrocentesis (ESSENTIAL):**
- **Synovial fluid analysis:**
  - **WBC >3,000/μL, PMN >70%** (suggests PJI)
  - **Culture** (aerobic + anaerobic, hold 14 days)
  - **α-defensin** (biomarker, high sensitivity/specificity)

**Intraoperative Cultures:**
- **≥3-5 tissue specimens** (separate samples)
- **Hold cultures 14 days** (slow-growing organisms like *Cutibacterium*)

**Imaging:**
- **X-ray:** Prosthesis loosening, periprosthetic lucency, periosteal reaction
- **Nuclear medicine:** Bone scan + WBC scan (if diagnosis unclear)
- **FDG-PET:** High sensitivity (but limited specificity early post-op)

### **Microbiology:**

**Most Common:**
- ***Staphylococcus aureus*** (MSSA/MRSA) - 30-40%
- **Coagulase-negative staphylococci (CoNS)** - 30-40%
- **Streptococci** - 10%
- ***Cutibacterium acnes*** (shoulder arthroplasty) - 10%
- **Gram-negatives** - 5-10%
- **Polymicrobial** - 10-20%

### **Treatment:**

**Surgical Management:**

**1. DAIR (Debridement, Antibiotics, Implant Retention):**

**Indications:**
- **Early infection** (<3 months post-op) OR **acute hematogenous** (<3 weeks symptoms)
- **Well-fixed prosthesis** (no loosening)
- **No sinus tract**
- **Pathogen susceptible** to oral biofilm-active antibiotics

**Procedure:**
- **Aggressive debridement, synovectomy**
- **Exchange modular components** (polyethylene liner)
- **Retain fixed components** (femoral stem, acetabular cup)

**Success Rate:** 50-70% (higher if *Streptococci*, lower if *S. aureus*)

**2. 2-Stage Exchange (Gold Standard for Chronic PJI):**

**Indications:**
- **Chronic infection** (>3 months)
- **Sinus tract**
- **Prosthesis loosening**
- **Failed DAIR**

**Procedure:**
- **Stage 1:** Remove prosthesis, debride, place antibiotic spacer (gentamicin/vancomycin-impregnated cement)
- **Antibiotics × 6 weeks** (IV initially, oral step-down)
- **Stage 2:** Reimplantation (after 6-12 weeks, infection markers normalized)

**Success Rate:** 80-90%

**3. 1-Stage Exchange:**
- **Selected cases** (known organism, susceptible, no sinus tract)
- **Emerging option** (fewer surgeries, lower cost)

**4. Resection Arthroplasty (Girdlestone):**
- **Remove prosthesis, no reimplantation**
- **Salvage option** (failed multiple surgeries, severe bone loss, immunocompromised)

**5. Amputation:**
- **Last resort** (uncontrolled infection, sepsis, failed all other options)

### **Antibiotic Therapy:**

**General Principles:**
- **Do NOT start antibiotics** before obtaining cultures (if elective surgery planned)
- **Prolonged duration** (3-6 months total)
- **Biofilm-active agents** (rifampin, fluoroquinolones, linezolid)

**Pathogen-Directed Regimens:**

***S. aureus* (MSSA) - DAIR:**
- **Nafcillin 2g IV q4h** OR **cefazolin 2g IV q8h × 2-6 weeks**
- **Then:** Rifampin 300-450mg PO BID + **levofloxacin 750mg PO daily** OR **TMP-SMX DS BID** × 3 months

***S. aureus* (MRSA) - DAIR:**
- **Vancomycin 15-20 mg/kg IV q8-12h × 2-6 weeks**
- **Then:** Rifampin 300-450mg PO BID + **TMP-SMX DS BID** OR **doxycycline 100mg BID** × 3 months

**CoNS - DAIR:**
- **Vancomycin × 2-6 weeks**
- **Then:** Rifampin 300-450mg PO BID + fluoroquinolone × 3 months

**Streptococci:**
- **Penicillin G 4 million units IV q4h** OR **ceftriaxone 2g IV daily × 4-6 weeks**
- **Oral:** Amoxicillin 1g PO TID × 3 months

***Cutibacterium acnes*:**
- **Penicillin G OR ceftriaxone × 6 weeks**
- **Oral:** Amoxicillin 1g PO TID × 3 months

**2-Stage Exchange:**
- **IV antibiotics × 4-6 weeks** (pathogen-directed)
- **"Antibiotic holiday"** (2-6 weeks off antibiotics before reimplantation)
- **Postoperative suppression** (3-6 months after stage 2)

**Duration:**
- **DAIR:** 3-6 months total (IV 2-6 weeks, then oral)
- **2-stage:** 4-6 weeks between stages, then 3-6 months after reimplantation

### **Prognosis:**

**Success Rates:**
- **DAIR:** 50-70%
- **2-stage exchange:** 80-90%
- **1-stage exchange:** 70-80%

**Predictors of Failure:**
- ***S. aureus*, Gram-negatives** (worse than Streptococci, CoNS)
- **Delayed diagnosis** (>3 weeks symptoms)
- **Immunocompromised**
- **Prosthesis loosening**

## Key Points

### **Early (<3mo) OR Acute Hematogenous = DAIR:**
- **Debridement, exchange modular components, retain prosthesis**
- **Rifampin + fluoroquinolone** OR **TMP-SMX × 3-6 months**

### **Chronic (>3mo) = 2-Stage Exchange:**
- **Remove prosthesis + antibiotic spacer**
- **IV antibiotics × 6 weeks, then reimplant**
- **Success 80-90%**

### **Diagnosis = Arthrocentesis + Cultures:**
- **Synovial WBC >3,000, PMN >70%**
- **≥2 positive cultures** (same organism)

### **Do NOT Start Antibiotics Before Cultures:**
- **If elective surgery planned** (wait for intraoperative cultures)

### **Rifampin for Biofilm:**
- ***S. aureus*, CoNS** (DAIR) - always add rifampin

### **Clinical Pearls:**
- **Early (<3mo) OR acute hematogenous:** DAIR + rifampin-based regimen × 3-6 months
- **Chronic (>3mo):** 2-stage exchange (gold standard, 80-90% success)
- **Arthrocentesis:** WBC >3,000, PMN >70%, culture × 2
- **Do NOT start antibiotics** before cultures (if elective surgery)
- **Rifampin essential** for biofilm (*S. aureus*, CoNS)
- **Hold cultures 14 days** (*Cutibacterium* slow-growing)

## Sources

- [IDSA: Prosthetic Joint Infection Guidelines 2024]
- [MSIS: Diagnosis and Management of PJI 2024]

## Media

N/A
